InVivoMAb anti-mouse CD16/CD32

Catalog number: BE0307_25mg
Brand: Bio X Cell
Packing: 25 mg
Other sizes: 5 mg
50 mg
100 mg
Price: € 1231.00
Expected delivery time: 7 days
Quantity:

Product specifications for - InVivoMAb anti-mouse CD16/CD32

Promotion: 
Promotion: The price displayed is only for academic or non-profit organizations. Please contact our helpdesk for regular prices.
Overview: 
Product group: Antibodies
Category: Primary Antibodies
Application: Neutralisation/Blocking
Species: Mouse
Host: Rat
Clonality: Monoclonal
Isotype: IgG2b Kappa
Properties: 
Molecular weight: 150 kDa
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352203
Concentration: 2-10 mg/ml
Scientific information: 
Scientific info: The 2.4G2 monoclonal antibody reacts specifically with mouse CD16 (Fc?RIII) and CD32 (Fc?RII). It has also been reported to react non-specifically via its Fc domain to Fc?RI. CD16 and CD32 are expressed on B cells, monocytes/macrophages, NK cells, granulocytes, mast cells, and dendritic cells. These receptors bind to the Fc portion of antibody-antigen complexes and play a role in adaptive immune responses. The 2.4G2 antibody is commonly used in flow cytometry staining experiments to prevent non-specific binding of IgG to the Fc?III and Fc?II, and possibly Fc?I, receptors prior to staining with antigen specific primary antibodies. The Fab fragments of the 2.4G2 antibody have also been used to block Fc receptors in vivo.
Clone ID: 2.4G2
Related products: 
Related products: Recommended Isotype Control(s): InVivoMab rat IgG2b isotype control (BE0090)
Recommended Dilution Buffer: InVivoPure pH 8.0 Dilution Buffer (IP0080)
Additional information: 
Synonyms: 2.4G2; BE0307; BioXCell
Liu X, Pu Y, Cron K, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015;21(10):1209-15. Read more
Arbelaez CA, Glatigny S, Duhen R, Eberl G, Oukka M, Bettelli E. IL-7/IL-7 Receptor Signaling Differentially Affects Effector CD4+ T Cell Subsets Involved in Experimental Autoimmune Encephalomyelitis. J Immunol. 2015;195(5):1974-83. Read more
Peske JD, Thompson ED, Gemta L, Baylis RA, Fu YX, Engelhard VH. Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat Commun. 2015;6:7114. Read more
Yu X, Menard M, Seabright G, Crispin M, Lazarus AH. A monoclonal antibody with anti-D-like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects. Transfusion. 2015;55(6 Pt 2):1501-11. Read more
Muppidi JR, Schmitz R, Green JA, et al. Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma. Nature. 2014;516(7530):254-8. Read more
Heesch K, Raczkowski F, Schumacher V, Hünemörder S, Panzer U, Mittrücker HW. The function of the chemokine receptor CXCR6 in the T cell response of mice against Listeria monocytogenes. PLoS ONE. 2014;9(5):e97701. Read more
León B, Bradley JE, Lund FE, Randall TD, Ballesteros-tato A. FoxP3+ regulatory T cells promote influenza-specific Tfh responses by controlling IL-2 availability. Nat Commun. 2014;5:3495. Read more
Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687-95. Read more